PRAP1 and neoplasm: Additionally, the tumor growth curve visually showed that mice injected with PRAP1-overexpressing HCT-116 cells developed resistance to cisplatin in comparison with the control group mice (P=0.0192; P=0.0006; P<0.0001) (Fig. 6B).